Results 81 to 90 of about 21,670 (174)

Curcumin in the Treatment of Various Diseases: Mechanism of Action, Bioavailability, Therapeutic Effects, and Current Clinical Trials

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Curcumin, a naturally occurring polyphenol, exhibits significant anti‐inflammatory and antioxidant capabilities. This review elucidates the specific molecular mechanisms by which curcumin exerts therapeutic effects on various diseases, including neurological disorders, cardiovascular diseases, cancers, inflammatory disorders, and autoimmune diseases ...
Lin Wang   +15 more
wiley   +1 more source

Carvedilol in hypertension treatment

open access: yes, 2008
Panagiotis C Stafylas, Pantelis A Sarafidis1st Department of Medicine, AHEPA University Hospital, Aristotle University, Thessaloniki, GreeceAbstract: Although β-blockers have been previously shown to effectively reduce blood pressure (BP) and have ...
Panagiotis C Stafylas   +1 more
core  

Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6-, CYP2C9- and CYP2C19-polymorphisms

open access: yes, 2011
Ziele: Carvedilol ist ein Betablocker der 3. Generation. Noch wenig bekannt ist der Zusammenhang zwischen der Abhängigkeit vom CYP2D6-Polymorphismus auf die Carvedilol-Pharmakokinetik und die Carvedilol-Pharmakodynamik.
Gültepe, Şenol   +6 more
core   +1 more source

Application of miscibility analysis and determination of Soluplus solubility map for development of carvedilol-loaded nanofibers [PDF]

open access: yes, 2017
Electrospinning was used to produce carvedilol-loaded Soluplus polymer nanofibers using a systematic approach. Miscibility between drug and polymer was determined through calculation of the interaction parameter, chi, and the difference between the total
Julijana Kristl   +11 more
core   +1 more source

HEART FAILURE, DIABETES, BETA-BLOCKERS AND RISK OF HYPOGLYCEMIA

open access: yesРациональная фармакотерапия в кардиологии, 2016
Aim. To evaluate an influence of carvedilol on risk of hypoglycemia in patients with diabetes type 2 (D2) and chronic heart failure (CHF) treated with angiotensin converting enzyme (ACE) inhibitors.Material and methods. 13 patients (10 men, 3 women; aged
A. A. Aleksandrov   +6 more
doaj   +1 more source

Population pharmacokinetics of carvedilol enantiomers and their metabolites in type-2 diabetes and healthy subjects [PDF]

open access: yes, 2017
Carvedilol, a drug available as a racemic mixture, is eliminated as hydroxyphenylcarvedilol (OHC) by CYP2D6 and O-desmethylcarvedilol (DMC) by CYP2C9 followed by conjugation to glucuronides.
Lanchote, VL   +3 more
core   +1 more source

Integrative Approaches in Cardiovascular Disease: The Role of Nutraceuticals in Heart Failure, Atrial Fibrillation, and Related Conditions

open access: yesPhytotherapy Research, Volume 40, Issue 11, Page 6249-6275, November 2026.
Schematic representation of the shared pathophysiological mechanisms underlying heart failure (HF) and atrial fibrillation (AF), including inflammation, oxidative stress, endothelial dysfunction, and fibrosis. The figure highlights the clinical and mechanistic convergence of conventional pharmacological therapies and selected nutraceuticals in ...
Laura Beatrice Mattioli   +6 more
wiley   +1 more source

Efficacy and safety of pharmacological interventions for the treatment of cocaine use disorder: A systematic review and network meta‐analysis

open access: yesAddiction, Volume 121, Issue 11, Page 2897-2958, November 2026.
Abstract Background and aims Cocaine use disorder (CUD) is an increasingly widespread concern worldwide. Various pharmacological treatments have been investigated for CUD, but their efficacy remains unclear, and none have been licensed for treatment.
Craig Paterson   +13 more
wiley   +1 more source

Adding carvedilol to ACE inhibitors may reduce arrhythmia and ventricular tachycardia following acute myocardial infarction. Commentary.

open access: yes, 2005
Comment on Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN ...
RAZZOLINI, RENATO, Renato Razzolini
core   +1 more source

Blood‐ and Liver Stiffness‐Based Non‐Invasive Tests for Clinically Significant Portal Hypertension in Patients With cACLD and HCC

open access: yesLiver International, Volume 46, Issue 11, November 2026.
ABSTRACT Background and Aims The applicability of non‐invasive tests (NITs) for clinically significant portal hypertension (CSPH) in patients with hepatocellular carcinoma (HCC) is controversial. We performed a head‐to‐head comparison of various NITs for CSPH and evaluated rule‐in/‐out criteria.
Lorenz Balcar   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy